Literature DB >> 3168323

Graves' disease: changes in TSH receptor and anti-microsomal antibodies after thyroidectomy.

T W De Bruin1, N A Patwardhan, R S Brown, L E Braverman.   

Abstract

It has been suggested that intrathyroidal plasma cells are the major site of TSH receptor antibody synthesis in Graves' disease (GD). To investigate this hypothesis, serial serum levels of TSH receptor antibodies, as determined by a recently developed immunoprecipitation assay (IPA), were measured in 13 patients with GD before and after subtotal thyroidectomy (Tx). Pretreatment TSH receptor antibody levels (86.4 +/- 26.8 pM/ml; mean +/- s.d.) decreased significantly due to antithyroid drug therapy to 60.3 +/- 21.5 pM/ml (P less than 0.05) just before Tx. However, 4 h after Tx, there was a significant increase (84.9 +/- 35.5 pM/ml; P less than 0.05) due to leakage of antibodies from the manipulated thyroid gland. After Tx, no major decrease in autoantibody levels occurred; TSH receptor antibodies were still detectable 1 to 7 months after Tx (88.7 +/- 44.6 pM/ml). Neither an acute change nor an overall reduction in anti-microsomal (M) antibody titres was observed after Tx. Our conclusions are that serum TSH antibody levels exhibited a drug-induced decrease before Tx and an immediate, but transient, post-operative increase. The post-operative increase was caused by leakage of preformed TSH receptor antibodies from the manipulated thyroid gland. Several months after Tx, TSH receptor and anti-M antibodies were present in the same serum concentrations as before treatment. The present data does not support the hypothesis that plasma cells in the thyroid gland are the major site of autoantibody synthesis in GD at the time of Tx.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168323      PMCID: PMC1541569     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Effect of therapy on serum thyroglobulin levels in patients with Graves' disease.

Authors:  R P Uller; A J Van Herle
Journal:  J Clin Endocrinol Metab       Date:  1978-05       Impact factor: 5.958

Review 2.  Immune mechanisms in Graves' disease.

Authors:  K D Burman; J R Baker
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

3.  TSH receptor antibody synthesis by thyroid lymphocytes.

Authors:  S M McLachlan; C A Pegg; M C Atherton; S L Middleton; F Clark; B Rees Smith
Journal:  Clin Endocrinol (Oxf)       Date:  1986-02       Impact factor: 3.478

4.  Evidence that thyroid-stimulating antibody is produced in the thyroid gland.

Authors:  P Kendall-Taylor; A J Knox; N R Steel; S Atkinson
Journal:  Lancet       Date:  1984-03-24       Impact factor: 79.321

5.  Solubilized human thyrotrophin receptors behave as one class of high-affinity binding sites.

Authors:  T W de Bruin; D van der Heide
Journal:  Mol Cell Endocrinol       Date:  1984-10       Impact factor: 4.102

Review 6.  Autoimmune thyroid disease: developments in our understanding.

Authors:  A P Weetman; A M McGregor
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

7.  Anti-thyrotrophin receptor antibodies in Graves' disease as demonstrated directly by immunoprecipitation assay.

Authors:  T W de Bruin; D van der Heide
Journal:  Acta Endocrinol (Copenh)       Date:  1983-01

8.  Evidence for thyroid antigen-reactive T lymphocytes infiltrating the thyroid gland in Graves' disease.

Authors:  T H Tötterman; L C Andersson; P Häyry
Journal:  Clin Endocrinol (Oxf)       Date:  1979-07       Impact factor: 3.478

9.  Thyroid glands in patients with Graves' disease are sources of thyrotropin-binding inhibitory (TBI) activity.

Authors:  M C Arqueros; H Niepomniszcze; J Moreno
Journal:  Acta Endocrinol (Copenh)       Date:  1986-07

10.  Further evaluation of an immunoprecipitation assay for TSH-receptor autoantibodies in Graves' disease.

Authors:  T W De Bruin; L E Braverman; R S Brown
Journal:  Metabolism       Date:  1986-12       Impact factor: 8.694

View more
  5 in total

1.  Clinical course and thyroid stimulating hormone (TSH) receptor antibodies during surgical treatment of Graves' disease.

Authors:  Y Mori; N Matoba; S Miura; N Sakai; Y Taira
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

Review 2.  The role of surgery in primary hyperthyroidism.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

3.  Graves' Disease that Developed Shortly after Surgery for Thyroid Cancer.

Authors:  Hea Min Yu; Soon Hyun Park; Jae Min Lee; Kang Seo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2013-09-13

4.  De Novo Extra-Thyroidal Manifestations of Graves' Disease presenting 16 Years after Total Thyroidectomy for Thyroid Cancer.

Authors:  Ann Kwee; Kai-Ling Yong; Lay Leng Seah; Chiaw-Ling Chng
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-08-10

5.  Graves' disease diagnosed in remnant thyroid after lobectomy for thyroid cancer.

Authors:  Meihua Jin; Ahreum Jang; Won Gu Kim; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Min Ji Jeon
Journal:  PLoS One       Date:  2022-03-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.